Your browser doesn't support javascript.
loading
Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273].
Reck, M; Ciuleanu, T-E; Cobo, M; Schenker, M; Zurawski, B; Menezes, J; Richardet, E; Bennouna, J; Felip, E; Juan-Vidal, O; Alexandru, A; Sakai, H; Lingua, A; Reyes, F; Souquet, P-J; De Marchi, P; Martin, C; Pérol, M; Scherpereel, A; Lu, S; Paz-Ares, L; Carbone, D P; Memaj, A; Marimuthu, S; Zhang, X; Tran, P; John, T.
Afiliação
  • Reck M; Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, LungClinic, Grosshansdorf, Germany. Electronic address: m.reck@lungenclinic.de.
  • Ciuleanu TE; Department of Oncology, Institutul Oncologic Prof Dr Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania.
  • Cobo M; Department of Medical Oncology, Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain.
  • Schenker M; Department of Oncology, SF Nectarie Oncology Center, Craiova, Romania.
  • Zurawski B; Department of Clinical Oncology, Ambulatorium Chemioterapii, Bydgoszcz, Poland.
  • Menezes J; Department of Oncology, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil.
  • Richardet E; Department of Clinical Oncology, Instituto Oncológico de Córdoba, Córdoba, Argentina.
  • Bennouna J; Department of Thoracic Oncology, University Hospital of Nantes and INSERM, CRCINA, Nantes, France.
  • Felip E; Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Juan-Vidal O; Department of Medical Oncology, Hospital Universitario La Fe, Valencia, Spain.
  • Alexandru A; Department of Oncology, Institute of Oncology Prof Dr Alexandru Trestioreanu Bucha, Bucharest, Romania.
  • Sakai H; Department of Thoracic Oncology, Saitama Cancer Center, Saitama, Japan.
  • Lingua A; Department of Medical Oncology, Instituto Medico Rio Cuarto, SA, Córdoba, Argentina.
  • Reyes F; Department of Medical Oncology, Fundación Arturo López Pérez, Santiago, Metropolitana, Chile.
  • Souquet PJ; Department of Pneumology, Hôpital Lyon Sud, Lyon, Pierre Bénite, France.
  • De Marchi P; Department of Oncology, Barretos Cancer Hospital, Barretos, Brazil.
  • Martin C; Department of Thoracic Oncology, Instituto Alexander Fleming, Buenos Aires, Argentina.
  • Pérol M; Department of Thoracic Oncology, Léon Bérard Cancer Center, Lyon, France.
  • Scherpereel A; Department of Pulmonary and Thoracic Oncology, University of Lille, CHU Lille, INSERM U1189, OncoThAI, Lille, France.
  • Lu S; Department of Medical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, China.
  • Paz-Ares L; Department of Medical Oncology, Hospital Universitario 12 de Octubre, CNIO-H12o Lung Cancer Clinical Research Unit, Universidad Complutense & CiberOnc, Madrid, Spain.
  • Carbone DP; Department of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, USA.
  • Memaj A; Bristol Myers Squibb, Princeton, USA.
  • Marimuthu S; Bristol Myers Squibb, Princeton, USA.
  • Zhang X; Bristol Myers Squibb, Princeton, USA.
  • Tran P; Bristol Myers Squibb, Princeton, USA.
  • John T; Department of Medical Oncology, Austin Hospital, Heidelberg, Australia.
ESMO Open ; 6(6): 100345, 2021 Dec.
Article em En | MEDLINE | ID: mdl-34864501
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article